Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever) - Full Text View

Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)

This study is ongoing, but not recruiting participants.

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00348361

Purpose

This study is aimed at validating key therapeutic targets and biomarkers associated with allergic rhinitis. The therapeutic target expression will be investigated after a 7 day course of corticosteroid treatment followed by allergen challenge.

Condition	Intervention	Phase
Allergic Rhinits	Drug: Fluticasone Propionate	Phase I

MedlinePlus related topics:

Fever Hay Fever

ChemIDplus related topics:

Fluticasone propionate Fluticasone

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacodynamics Study

Official Title:	A Study to Validate Key Therapeutic Targets and Biomarkers During Allergen Exposure in Subjects With Allergic Rhinitis

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Change in expression of key allergy targets in the nose following exposure to allergen. Assessment of protein expression measured by western blotting and immunohistochemistry in nasal biopsy tissue.

Secondary Outcome Measures:

Effect of corticosteroids treatment on the change in target expression following allergen challenge. Nasal lavage fluid and nasal secretions will be measured by ELISA and chemiluminescent assay.

Estimated Enrollment:	48
Study Start Date:	April 2005

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

No signs or symptoms of rhinitis outside of the relevant airborne allergen season.

Exclusion criteria:

History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessments.
Symptoms of rhinitis at inclusion indicated by total VAS score of >40 for the combined symptoms scores for blockage, rhinorrhoea, sneezing, itching) or a single symptom with a VAS score >20.
Subjects not showing a nasal response to allergen concentration =< 10,000 BU/ml.
Subjects with positive skin prick test for Dust House Mite.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00348361

Locations


United Kingdom
	GSK Clinical Trials Call Center
	London, United Kingdom, WC1X 8DA

Sponsors and Collaborators

GlaxoSmithKline

Investigators


Study Director:	GSK Clinical Trials, MD,MSc, FPPM	GlaxoSmithKline

More Information

Study ID Numbers:	ELR100710
First Received:	June 30, 2006
Last Updated:	April 24, 2007
ClinicalTrials.gov Identifier:	NCT00348361
Health Authority:	United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:

Hay fever

biomarkers

Study placed in the following topic categories:

Fever

Otorhinolaryngologic Diseases

Respiratory Tract Infections

Respiratory Tract Diseases

Rhinitis, Allergic, Seasonal

Fluticasone

Rhinitis

Additional relevant MeSH terms:

Anti-Inflammatory Agents

Respiratory System Agents

Autonomic Agents

Therapeutic Uses

Physiological Effects of Drugs

Anti-Asthmatic Agents

Anti-Allergic Agents

Peripheral Nervous System Agents

Dermatologic Agents

Bronchodilator Agents

Pharmacologic Actions

Nose Diseases

ClinicalTrials.gov processed this record on September 05, 2008